No Data
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
Express News | Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-Z), an in Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (Attr) Amyloidosis
Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $90
Intellia Therapeutics' NTLA-2001 Program: Promising Treatment With Strong Buy Recommendation
Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $56